Metabolic adaptation of glucose-deprived macrophages involves partial gluconeogenesis

K Katharina Schindlmaier (Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz) T Theresa Haitzmann (Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz) V Visnja Bubalo (Division of Pulmonology, Department of Internal Medicine, Medical University of Graz) B Barbara Konrad (Division of Pulmonology, Department of Internal Medicine, Medical University of Graz) J Joseph Jelwan (Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz) G Gabriele Bluemel (Department of Biosciences and Medical Biology, Bioanalytical Research Labs, University of Salzburg) S Sonja Rittchen (Division of Immunology, Otto Loewi Research Center, Medical University of Graz) V Vanessa Jäger (Division of Oncology, Department of Internal Medicine, Medical University of Graz) M Michael A. Dengler (Division of Oncology, Department of Internal Medicine, Medical University of Graz) L Luka Brcic (Diagnostic and Research Institute of Pathology, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz) J Jörg Lindenmann (Lung Research Cluster, Medical University of Graz) L Leigh M. Marsh (Lung Research Cluster, Medical University of Graz) T Thomas O. Eichmann (Core Facility Mass Spectrometry, Medical University of Graz) A Alexander Kirchmair (Biocenter, Institute of Bioinformatics, Medical University of Innsbruck) Z Zlatko Trajanoski J Julia Kargl (Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz) C Cristina Muñoz-Pinedo (Preclinical and Experimental Research in Thoracic Tumors, Bellvitge Biomedical Research Institute) K Katharina Leithner (Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz)

Abstract

Macrophages are recruited to sites of infection contributing to the killing of bacteria, but also to malignant tumors, where they promote angiogenesis and suppress antitumor immune responses. The metabolic microenvironment in tumors is frequently depleted of important nutrients such as glucose. Here, we investigated metabolic adaptation strategies of macrophages to glucose deprivation using stable isotopic tracing. Lactate production was decreased, potentially indicating a reduction of glycolysis. In contrast, the contribution of glutamine to the tricarboxylic acid cycle via α-ketoglutarate and reductive carboxylation were increased. Moreover, gluconeogenesis, the reverse pathway of glycolysis, was activated in glucose-deprived macrophages, proceeding partially to the generation of glycolytic intermediates and glycerol-3-phosphate. The partial gluconeogenesis pathway was abrogated in human and murine macrophages lacking the initial gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PCK2, mitochondrial isoform). Partial gluconeogenesis was higher in anti-inflammatory, interleukin-4-stimulated compared to proinflammatory, interferon-γ/lipopolysaccharide-stimulated macrophages. Single-cell analysis and immunostaining revealed expression of PCK2 in macrophages from both lung cancer and normal lung. Low glucose conditions only partially modulated macrophage phenotypes, leading to reduced CD80 surface marker levels in proinflammatory, and enhanced vascular endothelial growth factor expression in anti-inflammatory macrophages. Our study reveals partial gluconeogenesis in glucose-deprived macrophages and shows that this versatile type of immune cells exhibits remarkable metabolic flexibility.

Article Details

Volume / Issue Vol. 122, Issue 44
Published November 04, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (18)

K

Katharina Schindlmaier

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz

T

Theresa Haitzmann

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz

V

Visnja Bubalo

Division of Pulmonology, Department of Internal Medicine, Medical University of Graz

B

Barbara Konrad

Division of Pulmonology, Department of Internal Medicine, Medical University of Graz

J

Joseph Jelwan

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz

G

Gabriele Bluemel

Department of Biosciences and Medical Biology, Bioanalytical Research Labs, University of Salzburg

S

Sonja Rittchen

Division of Immunology, Otto Loewi Research Center, Medical University of Graz

V

Vanessa Jäger

Division of Oncology, Department of Internal Medicine, Medical University of Graz

M

Michael A. Dengler

Division of Oncology, Department of Internal Medicine, Medical University of Graz

L

Luka Brcic

Diagnostic and Research Institute of Pathology, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz

J

Jörg Lindenmann

Lung Research Cluster, Medical University of Graz

L

Leigh M. Marsh

Lung Research Cluster, Medical University of Graz

T

Thomas O. Eichmann

Core Facility Mass Spectrometry, Medical University of Graz

A

Alexander Kirchmair

Biocenter, Institute of Bioinformatics, Medical University of Innsbruck

Z

Zlatko Trajanoski

J

Julia Kargl

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz

C

Cristina Muñoz-Pinedo

Preclinical and Experimental Research in Thoracic Tumors, Bellvitge Biomedical Research Institute

K

Katharina Leithner

Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz